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Abstract 
Over the last few years, as more and more sequencing studies have been performed, it has become apparent that the identification 
of pathogenic mutations is, more often than not, a complex issue. Here, with a focus on neurodegenerative diseases, we have 
performed a survey of coding genetic variability that is unlikely to be pathogenic. 
We have performed whole-exome sequencing in 478 samples derived from several brain banks in the United Kingdom and the 
United States of America. Samples were included when subjects were, at death, over 60 years of age, had no signs of neurological 
disease and were subjected to a neuropathological examination, which revealed no evidence of neurodegeneration. This information 
will be valuable to studies of genetic variability as a causal factor for neurodegenerative syndromes. We envisage it will be 
particularly relevant for diagnostic laboratories as a filter step to the results being produced by either genome-wide or gene-panel 
sequencing. We have made this data publicly available at www.alzforum.org/exomes/hex. 
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Introduction 
One of the most important objectives in medical research is the complete 
understanding of how genetic variability influences a specific phenotype 
or trait. Methods to accomplish this at a genomic level have become 
available over the last decade with the introduction of genome-wide 
genotyping and “next-generation” sequencing (Bras et al., 2012).  
The widespread adoption and application of sequencing technologies 
allows two main types of studies: 1) sequencing of large cohorts of cases 
and controls to perform association studies with virtually complete 
genomic information; and 2) sequencing of individuals from families 
where a specific disease segregates. If the first application requires the 
analysis of as many individuals as possible, the second one requires 
instead a strict filtering of variants to allow for the identification of the 
causative one(s) (Goldstein et al., 2013). 
As sequencing technologies have matured over the last few years, the 
main issue researchers have faced has changed from dealing with false 
positive findings to dealing with the sheer number of true positive results. 
Because of the large number of rare, and sometimes private variants, it is 
often difficult to determine if a specific variant is benign in nature or if, 
instead, it is pathogenic (Biesecker et al., 2012).  
The most common approach to filter variants has been to use publicly 
available databases of genetic data, such as the 1000Genomes (Abecasis 
et al., 2010), the Exome Aggregation Consortium (ExAC; URL: 
http://exac.broadinstitute.org/) or more recently the genome Aggregation 
Database (gnomAD: http://gnomad.broadinstitute.org/) because these 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/270686doi: bioRxiv preprint first posted online Feb. 23, 2018; 
Guerreiro et al. - preprint copy - BioRxiv 
2 
resources provide users with genetic variability data on large numbers of 
individuals (Lek et al. 2016). 
Although this type of databases is very powerful, it should be noted that 
they do not provide detailed phenotypic information on the subjects 
included. For example, although cohort-level disease information is 
sometimes included, they do not provide individual-level information 
(such as the ages of the participants). This is essential information for 
studies that deal with diseases that occur later in life, as is the case for 
many neurodegenerative diseases. It is not clear, for example, how many 
samples have developed dementia since their inclusion in these 
studies/cohorts. As such, using these data to naively filter variants from 
cases presenting with any form of dementia can bias the results. 
Consequently, there is a need for a resource that allows researchers to 
confidently filter out variants from their own family-based sequencing 
studies, without the risk of excluding potentially disease-causing 
mutations. To address this issue, and focusing on neurodegenerative 
disorders, we are performing whole-exome sequencing in brain tissue 
samples from individuals who lived to old age and had no signs of overt 
neurodegeneration on neuropathological examination (Braak stage <= 
II).  
Here, we present results from the first public release of this dataset and 
describe the resource where the data is made publicly available 
(www.alzforum.org/exomes/hex). 
Results 
The data present herein is based on high-coverage exome-sequencing 
data from 478 elderly individuals who presented no signs of 
neurodegeneration when subjected to a post-mortem neuropathological 
examination. We have generated an average of 9Gb of data per 
individual, which translates into a mean coverage of the exome portion 
of the genome of 57x and leading to the identification of a total of 
1,145,559 high-quality variants with 276,997 of these variants directly 
affecting the coding sequence.  
Variants in known neurodegenerative disease genes 
One of the most important aspects of this resource is that it enables 
researchers to identify rare genetic variability in known disease-causing 
genes and immediately be aware that that variability will not account for 
a neurodegenerative disorder.  
Of the variability identified in known neurodegenerative disease genes a 
few should be highlighted: two novel variants in PSEN2, nine novel 
variants in LRRK2 and the variants p.Val476Ala and p.Thr763Ala in 
VPS35, for which reported minor allele frequencies are very low in 
ExAC (4.118e-05 and 8.236e-06, respectively). Each of these variants, if 
found in affected cases with the corresponding diseases, could be 
classified as disease causing, but the fact that we see them in HEX 
strongly argues against that interpretation. In addition to novel and low 
frequency variants, we have also identified variants that are reported to 
be pathogenic: the p.Ser163Leu and the p.Asp472Ala in PSEN2 are both 
seen in our cohort, as is p.Arg1628Pro in LRRK2, implying they are not 
fully penetrant disease-causing mutations in the Caucasian population. 
Genes with loss-of-function variants 
Similarly, it is also of great importance to understand, for 
neurodegenerative diseases, how many and which genes can be tolerated 
to have either one or two loss-of-function (LOF) alleles. We have 
identified 15,829 LOF sites, with 1,442 being LOF homozygous in at 
least 1 sample. Looking at single nucleotide variants specifically, given 
the higher error rates in indel calling, there are 3,472 nonsense variants 
with 273 being homozygous in at least one sample; 160 stop-loss, of 
which 32 are homozygous in at least one sample. Among the single 
nucleotide variants that are predicted as loss of function, 1,716 are novel 
as of dbSNP142. These variants represent a background of data where we 
know loss of function is unlikely to give rise to neurodegenerative 
disease.  
Variants previously described to be disease causing 
To search for variants that have been reported as disease causing for 
neurological syndromes, we used dbSNP’s variant annotation of 
pathogenicity based on the 30/10/2017 build of the clinvar file 
(ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh37). A total of 696 
individual variants from our cohort are annotated in dbSNP as being 
pathogenic. 
As selected examples, and in addition to the two PSEN2 and LRRK2 
mutations mentioned above, we identified one sample presenting a 
known pathogenic mutation in SCN9A (p.Asn642Tyr; rs121908918). 
This gene is responsible for a range of neurological conditions 
(OMIM:603415), and this particular mutation was associated with a 
broad clinical spectrum including generalized epilepsy and febrile 
seizures (Singh et al., 2009). A previously reported pathogenic mutation 
in SNCB was also identified in this cohort (p.Pro123His; rs104893937). 
This mutation was reported to cause dominant Lewy Body dementia 
(Ohtake et al., 2004). Three individuals (ages at death ranging from 73 to 
83 years) presented with the p.Arg468His mutation (rs138382758) in 
MFN2, previously described to cause Charcot-Marie-Tooth disease in a 
dominant fashion (Casasnovas et al., 2010). Finally, we identified a 
single case presenting the p.Pro80Leu variant in CHCHD10 a known 
cause of FTLD/ALS in an individual with age at death over 80 years. 
Public release of data as HEX (Healthy EXomes database) 
A resource such as this has tremendous potential in enabling researchers 
and molecular diagnosticians to perform much more complete and 
confident filtering of genetic variants. We have made this data publicly 
available as part of Alzforum at www.alzforum.org/exomes/hex. This 
offers the added benefit of allowing the user to integrate different types 
of information from a variety of sources and databases, without leaving 
the same website. 
Discussion 
Over the past few years we have been committed to study benign genetic 
variability in genes known to cause dementia in order to better understand 
the pathogenic role of each variant in these genes. To do this, we have 
systematically reassessed the pathogenicity of variants described in the 
genes known to more frequently harbor Alzheimer’s disease and 
frontotemporal dementia causative mutations (APP, PSEN1, PSEN2, 
GRN and MAPT) (Guerreiro et al., 2010a; Guerreiro et al., 2010b). To 
follow up that work we have now performed exome sequencing in 478 
samples from elderly individuals who presented no signs of 
neurodegeneration on post-mortem neuropathological examination. 
Given that we now know that plaque and tangle pathology occur 10-20 
years prior to clinical onset of disease, even the younger individuals in 
our cohort would be unlikely to develop disease for at least 15-20 years 
(Weiner MW et al., 2017).  Because of the sample selection that was 
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performed, each of the variants present in this cohort is highly unlikely 
to be a penetrant causal mutation for a neurodegenerative condition. 
It is often difficult to establish pathogenicity for novel genetic variants 
and several examples of miss-assignment of pathogenicity to benign 
variants can be found in the literature. The most common example is to 
assign pathogenicity to variants simply because they are found in genes 
that have been previously associated with a particular disease. This can 
be problematic from a clinical genetics perspective because it can lead to 
incorrect information being given to patients and family members; but it 
is also problematic from a fundamentally scientific perspective, because 
it has the potential to mislead research on the basic mechanisms 
underlying pathological processes. As an example, the MAPT variant p. 
Ala239Thr (rs63750096), found in two of HEX samples, was initially 
observed in an FTD patient with atypical brain pathology (Pickering-
Brown et al., 2002). This variant was considered to be pathogenic until 
GRN was found to be associated with FTD and subsequent sequencing of 
GRN in this case revealed the presence of a partial deletion of exon 11 
(Pickering-Brown et al., 2006). The finding of this probable null mutation 
in GRN in combination with FTD tau negative pathology clearly pointed 
to a pathogenic role of the GRN mutation and a benign nature of the 
MAPT variant. 
It should be noted that no validation of individual variants was performed 
for any of the variants identified. It is thus possible that some of the 
variants we identify are false-positives. Some of these may be derived 
from regions of low sequencing coverage, while others will be 
technology dependent errors. The latter will also be a useful resource for 
researchers working on the same type of data, as identifying false 
positives is not always easy, particularly when one does not have access 
to large numbers of samples sequenced using the same technology. 
The main objective of the HEX database is not to perform extensive 
validation of which variants may or may not be disease causing, instead 
we aim to provide a resource of genetic variability, created using well 
established analytical approaches, that was generated from very well 
characterized control samples for neurodegenerative diseases. The 
identification of variants of unknown pathogenicity, or even ones 
previously reported to be pathogenic, will be one of the major aspects of 
HEX, but also identifying genes that can tolerate loss-of-function variants 
and amino-acid positions that can be variable in the genome, with no 
effect on causing a neurodegenerative condition. 
It should be noted that low frequency, mid to high-risk variants are 
expected to be seen in HEX. Examples of this would be the p.Asn409Ser 
variant in GBA, or the p.Arg47His variant in TREM2, since neither of 
them is disease-causing in a dominant manner and, much like the 
epsilon4 allele of APOE in Alzheimer’s disease, having these variants 
alone is neither sufficient nor necessary for the development of 
Parkinson’s or Alzheimer’s diseases. Additionally, it is also plausible that 
causative variants with incomplete penetrance are present in the database, 
and this should be taken into account if the mode of inheritance of the 
samples being studied suggests incomplete penetrance. Thus, risk 
variants, both high and low risk, are expected to be seen in HEX, albeit 
with a lower frequency than in the general population.  
In summary, we describe a resource of genetic data, derived from samples 
of individuals who were of old age at time of death and who had no signs 
of neurodegeneration on neuropathological examination, and we make 
these data publicly available. We fully expect to continue to grow this 
database by including more samples and updating analytical tools as 
better methods are developed. 
 
Materials and Methods 
Sample selection 
We have currently included 478 samples derived from several UK and US brain 
banks. As inclusion criteria we used the following: 1) age at death > 60 years; 2) 
no clinical symptoms of neurodegenerative disease; 3) normal neuropathological 
examination (since some samples were derived from individuals > 85 years, we 
have included samples with Braak staging of up to II in some cases); 4) unrelated 
individuals. 
Sample preparation and sequencing 
DNA was extracted from frozen brain homogenates according to standard 
practices. Libraries were prepared according to Illumina’s TruSeq 
recommendations and sequenced on the HiSeq2000 on 2x100 base pair reads.  
Data analysis 
Raw fastq files were processed according to GATK’s Best Practices. In short, 
reads were aligned using bwa (Li and Durbin, 2009), optical duplicates were 
excluded using picard (http://picard.sourceforge.net/), local realignment around 
indels and base quality score recalibration were performed using GATK v3.4 
(Depristo et al., 2011; McKenna et al., 2010). Variant calling was performed 
simultaneously for SNPs and InDels using GATK’s v3.4 HaplotypeCaller in 
gVCF mode for individual samples. Genotype likelihoods were then used from the 
entire cohort to perform joint genotyping. Variants were separated into SNPs and 
InDels and variant recalibration was processed for each type of variability 
independently (Van der Auwera et al., 2013). Passing filter variants were 
annotated using Ensembl’s VEP (McLaren et al., 2010). 
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